- Home
- TMP vs SVRA Comparison
TMP vs SVRA Comparison
Compare TMP & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMP | SVRA |
|---|---|---|
| Founded | 1836 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2009 |
Fundamental Metrics
Financial Performance| Metric | TMP | SVRA |
|---|---|---|
| Price | $83.30 | $5.33 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $87.00 | $7.33 |
| AVG Volume (30 Days) | 51.7K | ★ 1.2M |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 11.24 | N/A |
| Revenue | ★ $75,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | $430.87 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $59.67 | $1.89 |
| 52 Week High | $86.95 | $7.01 |
Technical Indicators
Market Signals| Indicator | TMP | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 48.75 |
| Support Level | $80.72 | $5.10 |
| Resistance Level | $86.69 | $6.15 |
| Average True Range (ATR) | 1.92 | 0.28 |
| MACD | -0.29 | -0.03 |
| Stochastic Oscillator | 36.42 | 34.71 |
Price Performance
Historical ComparisonAbout TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).